HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

COL-3 benefits patients with AIDS-related Kaposi's sarcoma.

AuthorsBryant Furlow
JournalThe Lancet. Oncology (Lancet Oncol) Vol. 7 Issue 5 Pg. 368 (May 2006) ISSN: 1470-2045 [Print] England
PMID16696161 (Publication Type: News)
Chemical References
  • Antineoplastic Agents
  • Matrix Metalloproteinase Inhibitors
  • Tetracyclines
  • tetracycline CMT-3
Topics
  • Acquired Immunodeficiency Syndrome (complications)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Clinical Trials, Phase II as Topic
  • Dose-Response Relationship, Drug
  • Humans
  • Matrix Metalloproteinase Inhibitors
  • Sarcoma, Kaposi (complications, drug therapy)
  • Tetracyclines (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: